

**APPENDIX A**

**Eligibility of Drugs for Extended Drug Supply**

Eligibility of Drugs for Extended Drug Supply			
Maximum Extended Supply	Cancer Drugs Eligible for Extended Supply (*providing conditions in policy are met)		Cancer Drugs NOT Eligible for Extended Supply (beyond 1 cycle or 1 month)
Two (2) Months	afatinib	larotrectinib	cyclophosphamide
	alectinib	lenvatinib	etoposide
	asciminib	lorlatinib	fludarabine
	axitinib	niraparib	lomustine
	azacitidine (Onureg®)	olaparib	melphalan
	brigatinib	osimertinib	mercaptopurine
	cabozantinib	palbociclib	procarbazine
	capecitabine	pegylated interferon	regorafenib
	ceritinib	pomalidomide	sorafenib
	crizotinib	ponatinib	temozolomide
	dabrafenib +/- trametinib	ribociclib	thioguanine
	decitabine/cedazuridine (Inqovi®)	ripretinib	tretinoin
	encorafenib +/- binimetinib	selinexor	
	entrectinib	selpercatinib	
	erlotinib	trametinib +/- dabrafenib	
	everolimus	trifluridine-tipiracil	
	gefitinib	vandetanib	
	gilteritinib	vemurafenib +/- cobimetinib	
lapatinib			
Three (3) Months <b>(**restricted to maximum 84 day supply through Health Canada regulated safety programs)</b>	acalabrutinib	<b>** lenalidomide</b>	Any drug given intravenously that requires administration within a treatment centre will not be provided or dispensed to patients for reasons of extended absence from the province.
	abiraterone	medroxyprogesterone	
	acitretin	megestrol acetate	
	apalutamide	memantine	
	clodronate	methotrexate	
	darbepoetin	mitotane	
	darolutamide	pazopanib	
	denosumab	ruxolitinib	
	enzalutamide	sunitinib	
	fedratinib	venetoclax	
	ibrutinib	<b>** vismodegib</b>	
idelalisib	zanubrutinib		
Four (4) Months	bosutinib		
	chlorambucil		
	nilotinib		
Six (6) Months	anagrelide	imatinib	
	anastrozole	lanreotide (Somatuline Autogel®)	
	bicalutamide	letrozole	
	cyproterone	leuprolide (Eligard® or Lupron®)	
	dasatinib	octreotide LAR	
	degarelix (Firmagon®)	tamoxifen	
	exemestane		
	flutamide		
	fulvestrant		
	goserelin (Zoladex LA®)		
	hydroxyurea		